Drugs as P-glycoprotein substrates, inhibitors, and inducers

Drug Metabolism Reviews

Volumn 34, Issue 1-2, 2002, Pages 47-54

  Kim, Richard B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMPRENAVIR; ANTIALLERGIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ATORVASTATIN; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CLOTRIMAZOLE; CYCLOSPORIN; DIGOXIN; ELACRIDAR; ERYTHROMYCIN; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; MACROLIDE; MORPHINE; NELFINAVIR; NIFEDIPINE; QUINIDINE; RETINOIC ACID; RIFAMPICIN; RITONAVIR; SAQUINAVIR; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; ZOSUQUIDAR;

DRUG ABSORPTION; DRUG DISPOSITION; DRUG MECHANISM; DRUG TRANSPORT; GENE FUNCTION; GENE IDENTIFICATION; GENE INDUCTION; GENE LOCATION; GENETIC CODE; MULTIDRUG RESISTANCE; NOMENCLATURE; NONHUMAN; PHARMACOGENETICS; PROTEIN DOMAIN; REVIEW;

ATP-BINDING CASSETTE TRANSPORTERS; GENES, MDR; HUMANS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PHARMACEUTICAL PREPARATIONS; TERMINOLOGY; TISSUE DISTRIBUTION;

EID: 0036229852     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-120001389     Document Type: Review

References (57)

1. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
2. Multidrug resistance P-glycoprotein, chemotherapy, episomes, gene, therapy. Genetic analysis of the multidrug transporter
3. Homozygous disrupting of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease
4. Biochemistry of multidrug resistance mediated by the multidrug transporter
5. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
6. Pharmacological insights from P-glycoprotein knockout mice
7. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
8. P-glycoprotein, a gatekeeper in the blood-brain barrier
9. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
10. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism
11. Normal viability and altered pharmacokinetics in mice lacking mdrl-type (Drug-Transporting) P-glycoproteins
12. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
13. The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a gene
14. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein
15. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
16. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice
17. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure
18. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
19. P-glycoprotein-mediated transcellular transport of MDR-reversing agents
20. Tsuruo direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells
21. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers
22. Testing the role of P-glycoprotein expression in clinical trials - Applying pharmacological principles and best methods for detection together with good clinical trials methodology
23. Reversal of multidrug resistance by the P-glycoprotein modulator LY335979, from the bench to the clinic
24. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells
25. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
26. Nuclear receptor response elements mediate induction of intestinal mdr1 by rifampin
27. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone
28. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion
29. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture
30. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor
31. Bromocriptine modulates P-glycoprotein function
32. Brain bilirubin content is increased in P-glycoprotein-deficient transgenic null mutant mice
33. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity
34. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: Evidence of cytochrome P-450 A and P-glycoprotein induction
35. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line caco-2
36. Increased brain P-glycoprotein in morphine tolerant rats
37. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
38. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats
39. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs
40. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole
41. Modulation of P-glycoprotein activity by glial factors and retinoic acid in an immortalized rat brain microvessel endothelial cell line
42. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator LY335979
43. The MDR1 gene product P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin
44. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells
45. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes
46. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
47. Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene
48. Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells
49. Adenosine triphosphate-dependent transport of estradiol-17beta(beta-D-glucuronide) in membrane vesicles by MDR1 expressed in insect cells
50. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine
51. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier
52. Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors
53. Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine
54. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
55. Resistance to tetracycline, a hydrophilic antibiotic is mediated by P-glycoprotein in human multidrug resistant cells
56. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption
57. Secretion of sparfloxacin from the human intestinal caco-2 cell line is altered by P-glycoprotein inhibitors